GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Burzynski Research Institute Inc (OTCPK:BZYR) » Definitions » Change In Receivables

BZYR (Burzynski Research Institute) Change In Receivables : $0.00 Mil (TTM As of Nov. 2024)


View and export this data going back to . Start your Free Trial

What is Burzynski Research Institute Change In Receivables?

Burzynski Research Institute's change in receivables for the quarter that ended in Nov. 2024 was $0.00 Mil. It means Burzynski Research Institute's Accounts Receivable stayed the same from Aug. 2024 to Nov. 2024 .

Burzynski Research Institute's change in receivables for the fiscal year that ended in Feb. 2024 was $0.00 Mil. It means Burzynski Research Institute's Accounts Receivable stayed the same from Feb. 2023 to Feb. 2024 .

Burzynski Research Institute's Accounts Receivable for the quarter that ended in Nov. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Burzynski Research Institute's liquidation value for the three months ended in Nov. 2024 was $-0.02 Mil.


Burzynski Research Institute Change In Receivables Historical Data

The historical data trend for Burzynski Research Institute's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Burzynski Research Institute Change In Receivables Chart

Burzynski Research Institute Annual Data
Trend Feb15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Burzynski Research Institute Quarterly Data
Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Burzynski Research Institute Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Nov. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Burzynski Research Institute  (OTCPK:BZYR) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Burzynski Research Institute's Days Sales Outstanding for the quarter that ended in Nov. 2024 is calculated as:

2. In Ben Graham's calculation of liquidation value, Burzynski Research Institute's accounts receivable are only considered to be worth 75% of book value:

Burzynski Research Institute's liquidation value for the quarter that ended in Nov. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.001-0.022+0.75 * 0+0.5 * 0
=-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Burzynski Research Institute Change In Receivables Related Terms

Thank you for viewing the detailed overview of Burzynski Research Institute's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Burzynski Research Institute Business Description

Traded in Other Exchanges
N/A
Address
9432 Katy Freeway, Houston, TX, USA, 77055
Burzynski Research Institute Inc operates primarily as a research and development facility of Antineoplaston drugs currently being tested for the use in the treatment of cancer, and provides consulting services.
Executives
Monika Szopa-paszkowiak director 9432 KATY FWY #200, HOUSTON TX 77055
Frederick Richard Schiff director 9432 KATY FREEWAY, HOUSTON TX 77055
Barbara Burzynski director, 10 percent owner 9432 KATY FREEWAY, HOUSTON TX 77055
Carlton Hazlewood director 9432 KATY FREEWAY, HOUSTON TX 77055
Patryk Goscianski officer: Secretary and Treasurer 9432 KATY FREEWAY, HOUSTON TX 77055
Gregory Burzynski director 9432 KATY FREEWAY, HOUSTON TX 77055
Tomasz Janicki officer: VP of Clinical Trials 9432 KATY FREEWAY, HOUSTON TX 77055
Michael Driscoll director 9432 KATY FREEWAY, HOUSTON TX 77055
Stanislaw Burzynski director, 10 percent owner, officer: President 9432 KATY FREEWAY, HOUSTON TX 77055
Dudley Reece Anderson officer: Chief Financial Officer 9432 OLD KATY RD., SUITE 200, HOUSTON TX 77055

Burzynski Research Institute Headlines

No Headlines